Alexandria Real Estate Equities, Inc. ARE has made its first seed funding investment in Cambridge-based Holobiome, Inc., under the company’s recently-launched Alexandria Seed Capital Platform.
In fact, the company is celebrating the inaugural member class of seed- and early-stage life science firms associated with its life-science start-up platform, Alexandria LaunchLabs. The platform opened its first location at Alexandria Center in One Kendall Square, Cambridge.
The 20,000-square-foot seed- and early-stage incubator, which opened last December, is currently home to 13 innovative member companies. At this life-science cluster, Alexandria provides flexible, cost-effective, move-in ready and well-equipped wet laboratory and office space. Further, it offers high-quality equipment and services, mentorship and programming, in addition to seed-capital access through Alexandria Seed Capital Platform, which is led by its venture capital business — Alexandria Venture Investments.
Impressively, on account of its efficient and responsible design, as well as construction practices Alexandria LaunchLabs – Cambridge is a LEED Gold certified campus. In addition, it achieved a Fitwel 3 Star Rating, demonstrating its ability to drive higher levels of member health, wellness and productivity.
Additionally, Alexandria has announced a call for applications for two Alexandria LaunchLabs Innovation Prizes, worth $125,000. This will recognize excellence in early-stage science, leadership and business strategy. The first prize is open for Massachusetts-based life-science entrepreneurs, and the second one will be awarded to academic spinouts nominated by local technology transfer offices. Entries will be accepted until May 31 and winners will be announced in June. The winners will receive $100,000 for research and development support. They will occupy office/laboratory space at Alexandria LaunchLabs – Cambridge for a year, worth an additional $25,000.
Such efforts come as part of the company’s expansion efforts to bank on the life-science real estate industry’s favorable fundamentals.
This Zacks #2 (Buy) Ranked stock has gained 19.5% over the past three months, outperforming 11.5% growth recorded by the industry.
Other Stocks to Consider
Investors can also consider other similarly-ranked stocks from the same space like Terreno Realty Corporation TRNO, Cousins Properties Incorporated CUZ and Boston Properties, Inc. BXP. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Terreno Realty’s funds from operations (FFO) per share estimates for 2019 remained unchanged at $1.42, in the past month. Furthermore, it has a long-term growth rate of 8.40%.
Cousins Properties’ Zacks Consensus Estimate for first-quarter 2019 FFO per share has remained unchanged at 20 cents in the past month. Also, it has a long-term growth rate of 3.50%.
Boston Properties’ FFO per share estimate for the ongoing year has been revised marginally north to $6.93 in 30 days’ time. Additionally, it has a long-term growth rate of 6.30%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cousins Properties Incorporated (CUZ) : Free Stock Analysis Report
Terreno Realty Corporation (TRNO) : Free Stock Analysis Report
Boston Properties, Inc. (BXP) : Free Stock Analysis Report
Alexandria Real Estate Equities, Inc. (ARE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research